Lv6
2518 积分 2024-10-22 加入
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma
6天前
已完结
Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates
14天前
已完结
Discovery of Novel N -Linked Camptothecin Linker-Payloads to Access Antibody–Drug Conjugates with High Target-Mediated In Vivo Efficacy
14天前
已完结
The next generation of antibody–drug conjugates
16天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
24天前
已完结
Multispecific T-cell engagers attract cancer drug developers
1个月前
已完结
New payloads drive next-gen antibody-drug conjugates
1个月前
已完结
Preclinical Development of MGC028, an ADAM9-Targeted, Glycan-Linked, Exatecan-Based Antibody–Drug Conjugate for the Treatment of Solid Cancers
2个月前
已完结
BCMA and GPRC5D/FcRH5 bispecific antibodies have different AE profiles
6个月前
已完结
Transforming toxins into treatments: the revolutionary role of α-amanitin in cancer therapy
6个月前
已完结
皖公网安备34019202002308
